DNA methylation state of the galectin-3 gene represents a potential new marker of thyroid malignancy

Oncology Letters

Volumn 6, Issue 1, 2013, Pages 86-90

  Keller, Simona ^a   Angrisano, Tiziana ^a   Florio, Ermanno ^a   Pero, Raffaela ^a   Decaussin Petrucci, Miriam ^b   Troncone, Giancarlo ^c   Capasso, Mario ^c   Lembo, Francesca ^a   Fusco, Alfredo ^a   Chiariotti, Lorenzo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITÉ LYON 1   (France)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

DNA methylation; Galectin 3; Human thyroid cancer; Tumor marker

Indexed keywords

BISULFITE; GALECTIN 3;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; DNA METHYLATION; GAL 3 GENE; GENE; GENE SEQUENCE; GENETIC TRANSCRIPTION; GOITER; HISTOGRAM; HUMAN; HUMAN TISSUE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POLYMERASE CHAIN REACTION; PYROSEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID CANCER; THYROID PAPILLARY CARCINOMA; TRANSCRIPTION INITIATION;

EID: 84878306201     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1312     Document Type: Article

References (36)

1. Hedinger C, Williams ED and Sobin LH: The WHO histological classification of thyroid tumours: a commentary on the second edition. Cancer 63: 908-911, 1989.
2. Kondo T, Ezzat S and Asa SL: Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6: 292-306, 2006.
3. Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer 12: 245-262, 2005.
4. Suarez HG, du Villard JA, Severino M, et al: Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 5: 565-570, 1990
5. Santoro M, Melillo RM, Grieco M, Berlingieri MT, Vecchio G and Fusco A: The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. Cell Growth Differ 4: 77-84, 1993.
6. de Nigris F, Cerutti J, Morelli C, et al: Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues. Br J Cancer 86: 917-923, 2002.
7. Melillo RM, Castellone MD, Guarino V, et al: The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115: 1068-1081, 2005.
8. Chiu CG, Strugnell SS, Griffith OL, et al: Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 176: 2067-2081, 2010.
9. Xu XC, el-Naggar AK and Lotan R: Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 147: 815-822, 1995.
10. Gharib H: Fine-needle aspirate biopsy of thyroid nodules: advantage, limitation and effect. Mayo Clin Proc 69: 44-49, 1994.
11. Bartolazzi A, Orlandi F, Saggiorato E, et al: Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol 9: 543-549, 2008.
12. Baylin SB: DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2 (Suppl 1): S4-S11, 2005.
13. Baylin S and Bestor TH: Altered methylation patterns in cancer cell genomes: cause or consequence? Cancer Cell 1: 299-305, 2002.
14. Czarnecka K, Pastuszak-Lewandoska D, Migdalska-Sek M, et al: Aberrant methylation as a main mechanism of TSGs silencing in PTC. Front Biosci (Elite Ed) 3: 137-157, 2011.
15. Hoque MO, Rosenbaum E, Westra WH, et al: Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab 90: 4011-4018, 2005.
16. 2 promoter in retinoic acid-resistant thyroid cancer cells. Oncogene 26: 4018-4024, 2007.
17. Ehrich M, Nelson MR, Stanssens P, et al: Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci USA 102: 15785-15790, 2005.
18. Keller S, Sarchiapone M, Zarrilli F, et al: Increased BDNF promoter methylation in the Wernicke area of suicide subjects. Arch Gen Psychiatry 67: 258-267, 2010.
19. Tost J and Gut IG: DNA methylation analysis by pyrosequencing. Nat Protoc 2: 2265-2275, 2007.
20. Keller S, Sarchiapone M, Zarrilli F, et al: TrkB gene expression and DNA methylation state in Wernicke area does not associate with suicidal behavior. J Affect Disord 135: 400-404, 2011.
21. Elisei R, Shiohara M, Koeffler HP and Fagin JA: Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitorsp15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer 83: 2185-2193, 1998.
22. Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP and Dammann R: Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res 62: 3698-3701, 2002.
23. Alvarez-Nuñez F, Bussaglia E, Mauricio D, et al: PTEN promoter methylationin sporadic thyroid carcinomas. Thyroid 16: 17-23, 2006.
24. Zuo H, Gandhi M, Edreira MM, et al: Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. Cancer Res 70: 1389-1397, 2010.
25. Hu S, Liu D, Tufano RP, et al: Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer 119: 2322-2329, 2006.
26. Graff JR, Greenberg VE, Herman JG, et al: Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. Cancer Res 58: 2063-2066, 1998.
27. Wiseman SM, Masoudi H, Niblock P, et al: Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg 191: 581-587, 2006.
28. Sassa M, Hayashi Y, Watanabe R, et al: Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer. Thyroid 21:511-517, 2011.
29. Xing M: BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28: 742-762, 2007.
30. Xing M: Gene methylation in thyroid tumorigenesis. Endocrinology 148: 948-953, 2007.
31. Kondo T, Nakazawa T, Ma D, et al: Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab Invest 89: 791-799, 2009.
32. Catalano MG, Fortunati N and Boccuzzi G: Epigenetics modifications and therapeutic prospects in human thyroid cancer. Front Endocrinol (Lausanne) 3: 40, 2012.
33. Venkataraman GM, Yatin M, Marcinek R and Ain KB: Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab 84: 2449-2457, 1999.
34. Xing M, Usadel H, Cohen Y, et al: Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res 63: 2316-2321, 2003.
35. Smith JA, Fan CY, Zou C, Bodenner D and Kokoska MS: Methylation status of genes in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 133: 1006-1011, 2007.
36. Galusca B, Dumollard JM, Lassandre S, Niveleau A, Prades JM, Estour B and Peoc'h M: Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia. Virchows Arch 447: 18-23, 2005.